Mergers, acquisitions and joint ventures are all significant stages in a business’s life cycle and none are without their risks and pitfalls.
Which is why you need a team of legal advisers who offer guidance and support on critical issues as well as high quality, practical advice on getting the deal done.
Our M&A team handles the full range of transactions from UK and cross-border acquisitions and divestments, to complex reorganisations and restructurings, joint ventures, management buy-outs and buy-ins, and corporate rescues (such as pre-packs) and distressed transactions. Our clients include UK and international quoted and private companies, financial services organisations, management teams and entrepreneurs.
For each transaction, we build bespoke partner-led teams delivering integrated advice from specialists across a full service including real estate, competition, tax, pensions and employment, intellectual property and IT.
Much of our work has an international angle and we will often project manage cross-border transactions, calling on a network of international lawyers to provide a seamless service whatever the complexities - be it for UK companies, or assisting corporates based in the US, Europe or Asia.
But it is not just about having a strong team of experts. It is also about our approach. We work tenaciously and creatively to find the best solution for our clients, and we ensure that matters proceed quickly and efficiently. We focus on getting a successful outcome.
News & Insights
COVID-19: Considerations for companies
An essential toolkit setting out key issues that companies and directors should consider during this uncertain time.
Charles Russell Speechlys advises Transense Technologies Plc on iTrack technology transaction with Bridgestone Corporation
Transense Technologies Plc, the provider of sensor systems for the industrial, mining and transportation markets.
Charles Russell Speechlys advise the shareholders of Veriton Pharma on its sale to SERB
We advised the shareholders of a private pharmaceutical company on its sale to SERB Specialty Pharmaceuticals.